Ophthalmic device trial guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA draft guidance entitled "Accountability Analysis for Clinical Studies for Ophthalmic Devices" published in the Aug. 4 Federal Register recommends that studies have 10% or less of patients lost to follow-up. Sponsors are advised to include a lost to follow-up analysis with a report on overall accountability. A suggested format to demonstrate overall accountability and "accountability by post-operative visit" also are included in the draft guidance. The deadline for comments is Nov. 2
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.